Invitation to Roche’s Virtual Neurology/ACTRIMS Investor Event

Roche is hosting a Virtual Neurology/ACTRIMS Investor Event on February 9, 2026, designed specifically for investors and analysts interested in the company’s neurology pipeline and latest clinical developments. The event will highlight new data from the Phase III FENtrepid study, which evaluates fenebrutinib versus Ocrevus (ocrelizumab) in patients with Primary Progressive Multiple Sclerosis (PPMS). This study represents a significant milestone in Roche’s ongoing commitment to advancing treatments for neurological disorders, particularly multiple sclerosis, which remains an area of high unmet medical need.

The event coincides with the ACTRIMS Forum 2026 (February 5–7, 2026), where the study results will be formally presented. Roche’s investor session will provide deeper insights into the implications of these findings, the company’s neurology pipeline strategy, and the broader outlook for innovation in MS treatment.

The agenda includes an introduction by Bruno Eschli, Head of Investor Relations, followed by a neurology pipeline update from Hideki Garren, SVP, Global Head of Product Development Neurology. The clinical presentation will be delivered by Dr. Amit Bar-Or, a leading neurologist and MS researcher from the University of Pennsylvania. The session will conclude with a Q&A segment, allowing participants to engage directly with Roche’s leadership and scientific experts.

This event is an opportunity for stakeholders to understand Roche’s positioning in the competitive MS treatment landscape, the potential of fenebrutinib as a novel therapy, and the company’s broader neurology development strategy. With the growing importance of targeted therapies and personalized medicine, Roche aims to demonstrate its leadership in advancing science and delivering value to patients and investors alike. Pre-registration is required, and a replay will be made available via Roche’s investor relations portal.